Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

被引：8
|
作者：
Koo, Rachel [1 ]
Lo, Jennifer [2 ]
Bock, Matthew J. [2 ]
机构：
[1] Loma Linda Univ Childrens Hlth, Dept Pediat, Loma Linda, CA USA
[2] Loma Linda Univ Childrens Hlth, Div Pediat Cardiol, Loma Linda, CA USA
来源：
CARDIOLOGY IN THE YOUNG | 2019年 / 29卷 / 06期
关键词：
Selexipag; infant; prostacyclin; pulmonary hypertension; paediatric;
D O I：
10.1017/S1047951119001082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
引用
收藏
页码：849 / 851
页数：3
相关论文
共 50 条
  • [41] ORAL TREPROSTINIL FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    de Lartigue, J.
    DRUGS OF TODAY, 2014, 50 (08) : 557 - 565
  • [42] Oral treprostinil in the treatment of pulmonary arterial hypertension
    Feldman, Jeremy
    Habib, Naomi
    Radosevich, John
    Dutt, Mohan
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1661 - 1667
  • [43] Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension
    Parikh, Kishan S.
    Doerfler, Sean
    Shelburne, Nicholas
    Kennedy, Karla
    Whitson, Jordan
    Dahhan, Talal
    Fortin, Terry
    Rajagopal, Sudarshan
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (04) : 299 - 304
  • [44] Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension
    Thurber, Kristina M.
    Williams, Breann M.
    Bates, Ruth E.
    Frantz, Robert P.
    PHARMACOTHERAPY, 2017, 37 (08): : E76 - E81
  • [45] Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension
    Bruderer, Shirin
    Hurst, Noemie
    Remenova, Tatiana
    Dingemanse, Jasper
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 743 - 751
  • [46] Safety concerns regarding selexipag in pulmonary arterial hypertension
    Greene, Rebecca A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (07) : 419 - 420
  • [47] A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension
    Sorensen, Louise M.
    Wehland, Markus
    Krueger, Marcus
    Simonsen, Ulf
    Nassef, Mohamed Z.
    Infanger, Manfred
    Grimm, Daniela
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (34) : 5191 - 5199
  • [48] Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
    Richter, Manuel J.
    Harutyunova, Satenik
    Bollmann, Tom
    Classen, Simon
    Fuge, Jan
    Gall, Henning
    Gerhardt, Felix
    Ghofrani, Hossein A.
    Gunkel, Hartmut
    Gruenig, Ekkehard
    Halank, Michael
    Heine, Alexander
    Klose, Hans
    Lange, Tobias J.
    Neurohr, Claus
    Nickolaus, Kai
    Opitz, Christian F.
    Rosenkranz, Stephan
    Seyfarth, Hans-Juergen
    Tello, Khodr
    Ewert, Ralf
    Olsson, Karen M.
    PULMONARY CIRCULATION, 2020, 10 (01)
  • [49] Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension
    Subías, PE
    Cea-Calvo, L
    de Menesses, RT
    Sánchez, MAG
    Jiménez, JFD
    de la Calzada, CS
    REVISTA ESPANOLA DE CARDIOLOGIA, 2003, 56 (08): : 818 - 821
  • [50] Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations
    Mathier, Michael A.
    McDevitt, Susanne
    Saggar, Rajan
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (11) : 1210 - 1217
12345